News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Trevena, Inc. Acute Heart Failure Drug TRV027 Unloads the Heart and Maintains Renal Function When Co-administered With Furosemide in Dog Heart Failure Model


9/4/2012 3:41:13 PM

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc., the leader in the discovery of G-protein coupled receptor (GPCR) biased ligands, announced that results have been published from a new preclinical pharmacology study of its phase 2 clinical acute heart failure molecule, TRV027. The study was the second to be published as part of a multi-year collaboration between Trevena and Drs. John C. Burnett, Jr, and Guido Boerritger, of the Mayo Clinic.

Read at BioSpace.com

Related News

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES